NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Newly Diagnosed Multiple Myeloma

Relapsed Refractory Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

Sponsor

Janssen Research & Development, LLC

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT04722146

Official Title: A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted : January 25, 2021

Click here for details on ClinicalTrials.gov